Antibe Therapeutics Inc(Pre-Merger) ATBPF

If we pass P2

[Duster340]

that makes us a lot less risky, i think that gets us a possble partnership deal and a lot closer to being a takeout candidate, many big players out there with deep pockets itching to make deals like bayer for one.)

 Many of the world’s largest pharmaceutical companies are sitting on significant cash piles and need to invigorate their pipelines of medicines, as key drugs go off patent before the end of the decade. Earlier on Monday, French pharmaceutical company Sanofi struck a deal to buy Type-1 diabetes treatment developer Provention Bio for $2.9bn, in a bid to bolster its drug pipeline after facing pressure from investors to make more acquisitions. Pfizer has been under pressure to do a big deal, after the company forecast that revenues would slump by a third to between $67bn to $71bn in 2023 owing to steep falls in sales of Covid vaccines and treatments. Despite a significant drop in biotech stocks over the past year, large pharmaceutical companies have shown little interest in picking up assets cheaply. Instead, they have tended to search for less risky companies, with drugs either on the market or